Symptomatic and clinical remission in patients with moderate, moderate... | Download Scientific Diagram
InDex's topical ulcerative colitis drug hits goal in phase 2b | Fierce Biotech
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis - Digestive and Liver Disease
New Drug Pipeline Monitor, 7th Edition - December 2015
Targeting Toll-like receptors: emerging therapeutics? | Nature Reviews Drug Discovery
David T. Rubin, MD on Twitter: "Lots of options coming for #IBD (here showing pipeline for #UC). Need patients to participate in clinical trials! https://t.co/j70EPGoyyt" / Twitter
Ulcerative Colitis Therapy Kappaproct Focus of InDex Presentations at Digestive Disease Week
JSB Market Research - PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022
Kappaproct for Ulcerative Colitis Presentation Set for 2016 UEGW
Frontiers | Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease | Medicine
Frontiers | Emerging Mechanisms of Innate Immunity and Their Translational Potential in Inflammatory Bowel Disease | Medicine
UC Therapy Candidate Kappaproct Shows Potential with New Data
Disease Analysis: Ulcerative Colitis - Research and Markets
Clinical efficacy of the Toll-like receptor 9 agonist cobitolimod using patient-reported-outcomes defined clinical endpoints in patients with ulcerative colitis - ScienceDirect
Pharmacological activity of DIMS0150. In the explorative phase IIa... | Download Scientific Diagram
Gendicine - an overview | ScienceDirect Topics
Kappaproct for Ulcerative Colitis Presentation Set for 2016 UEGW
InDex's topical ulcerative colitis drug hits goal in phase 2b | Fierce Biotech
Symptomatic and clinical remission in patients with normal and elevated... | Download Scientific Diagram
Paediatric ulcerative colitis drug gets orphan designation
The IBD Therapeutic Pipeline Is Primed to Produce - Practical Gastro
